Longeveron (LGVN) announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application for its stem cell therapy laromestrocel as a potential treatment for pediatric dilated cardiomyopathy. The accepted IND application provides for moving directly to a single Phase 2 pivotal registration clinical trial.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGVN:
- Longeveron appoints Powell as Chief Business Officer
- Positive Buy Rating for Longeveron Driven by Phase 2b Study Milestone and Favorable Market Conditions
- Longeveron completes enrollment of Phase 2b trial of laromestrocel in HLHS
- Longeveron Elects New Director at Annual Meeting
- Longeveron management to meet with Roth MKM